Summary & Overview
HCPCS Level II J1710: Hydrocortisone Sodium Phosphate Injection, up to 50 mg
HCPCS Level II code J1710 identifies the administration of hydrocortisone sodium phosphate, up to 50 mg, as a parenteral corticosteroid dose. This code is used on medical claims to document the drug administered rather than durable equipment or procedure codes, making it relevant for billing of short-course anti-inflammatory and immunosuppressive treatments across ambulatory and hospital outpatient settings. Nationally, accurate coding of injectable corticosteroids affects payment, clinical documentation, and tracking of drug utilization.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for hydrocortisone injection, typical sites of service, and the aspects of claims reporting that influence billing outcomes. The publication outlines common modifiers associated with parenteral drug administration when relevant, summarizes payer coverage patterns where available, and highlights benchmarks and policy considerations that affect reimbursement and claim adjudication for injectable medications.
The content is intended to inform billing staff, practice managers, and policy analysts about the purpose of J1710, its role in claims, and the practical documentation elements tied to injectable corticosteroid services. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J1710 represents an injection of hydrocortisone sodium phosphate, up to 50 mg. The service is a single-dose parenteral administration of a corticosteroid formulation intended for anti-inflammatory or immunosuppressive indications.
Service type: Injection / Parenteral Pharmacologic Administration
Typical site of service: Outpatient clinic, physician office, urgent care, or hospital outpatient department
Clinical & Coding Specifications
Clinical Context
A typical patient is a 55-year-old outpatient presenting to an ambulatory infusion center or physician office for an intramuscular or soft-tissue injection of hydrocortisone sodium phosphate for acute inflammatory symptoms. Common presenting complaints include severe allergic reaction with localized swelling, acute gout flare with localized soft-tissue inflammation, or sharply painful bursitis or tendonitis not controlled with oral therapy. The clinical workflow: clinician documents history and indication, reviews contraindications and allergies, obtains informed consent for injection, selects appropriate dose (up to 50 mg per J1710), prepares sterile medication, and administers injection via intramuscular or periarticular route. Observation for immediate adverse reaction follows (typically 15–30 minutes). Documentation includes medication name, dose, route, lot number, site of injection, patient tolerance, and associated diagnosis code(s). Billing uses J1710 for the drug supply; facility or professional service codes for administration and any associated procedure codes or evaluation services are billed separately, with applicable modifiers appended when clinically appropriate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than typical for drug administration due to complexity, prolonged time, or complications. |